November 13, 2023 Pharmacosmos appoints Henrik Parker as Chief Financial Officer (CFO) and member of the Executive Management, effective 13 November 2023.

Pharmacosmos is pleased to announce Henrik Parker as its new Chief Financial Officer. Henrik succeeds Robert Guglielmetti, who has decided to step down after 19 years in the CFO role. Robert will stay with Pharmacosmos in a new role as Senior Director, Finance. 

Henrik Parker is an experienced finance executive and State Authorised Public Accountant with extensive financial experience including within the pharmaceutical industry, through his former role as Corporate Vice President of Corporate Accounting at Novo Nordisk. In this role, Henrik was responsible for external financial reporting, internal financial controls, and payroll for all Danish employees, leading a department of 40 employees. 

Henrik’s other experience includes serving as Vice President of Group Reporting & FP&A at Falck Group as well as the role as interim CFO at DUOS Gruppen. Henrik started his career at KPMG, where he worked for several years in Denmark and London. 

“Following a thorough external search, we are pleased to welcome Henrik to Pharmacosmos Executive Management. I am confident that Henrik’s international experience in both pharma and other industries will benefit our organisation as we continue to grow. I would also like to thank Robert for his outstanding contributions to Pharmacosmos over the last two decades.” said Tobias S. Christiansen, President, and CEO, Pharmacosmos.

For more information, please contact:
Ditte Lindboe, Vice President, HR
+45 4164 4648

About Pharmacosmos Group

Pharmacosmos Group, headquartered in Holbaek, Denmark, and founded in 1965, is a highly specialised company focused on carbohydrate chemistry and a global leader in the development of innovative treatments for patients suffering from iron deficiency and iron deficiency anaemia. With companies in the UK, Nordics, Germany, the USA, and China, as well as through partners, Pharmacosmos markets its products around the world. With a strong and ongoing commitment to R&D, Pharmacosmos is able to leverage a unique carbohydrate production platform along with deep expertise in the synthesis of iron-carbohydrate complexes. The Pharmacosmos Group has more than 500 employees.


Please identify if you are a: